These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

473 related articles for article (PubMed ID: 22975379)

  • 1. Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells.
    Domingo-Domenech J; Vidal SJ; Rodriguez-Bravo V; Castillo-Martin M; Quinn SA; Rodriguez-Barrueco R; Bonal DM; Charytonowicz E; Gladoun N; de la Iglesia-Vicente J; Petrylak DP; Benson MC; Silva JM; Cordon-Cardo C
    Cancer Cell; 2012 Sep; 22(3):373-88. PubMed ID: 22975379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversal of docetaxel resistance in prostate cancer by Notch signaling inhibition.
    Qiu S; Deng L; Bao Y; Jin K; Tu X; Li J; Liao X; Liu Z; Yang L; Wei Q
    Anticancer Drugs; 2018 Oct; 29(9):871-879. PubMed ID: 29944470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition.
    Iannelli F; Roca MS; Lombardi R; Ciardiello C; Grumetti L; De Rienzo S; Moccia T; Vitagliano C; Sorice A; Costantini S; Milone MR; Pucci B; Leone A; Di Gennaro E; Mancini R; Ciliberto G; Bruzzese F; Budillon A
    J Exp Clin Cancer Res; 2020 Oct; 39(1):213. PubMed ID: 33032653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR/Notch Antagonists Enhance the Response to Inhibitors of the PI3K-Akt Pathway by Decreasing Tumor-Initiating Cell Frequency.
    Fu W; Lei C; Yu Y; Liu S; Li T; Lin F; Fan X; Shen Y; Ding M; Tang Y; Ye X; Yang Y; Hu S
    Clin Cancer Res; 2019 May; 25(9):2835-2847. PubMed ID: 30670492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of hedgehog signaling improves the anti-carcinogenic effects of docetaxel in prostate cancer.
    Mimeault M; Rachagani S; Muniyan S; Seshacharyulu P; Johansson SL; Datta K; Lin MF; Batra SK
    Oncotarget; 2015 Feb; 6(6):3887-903. PubMed ID: 25682877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence of a novel docetaxel sensitizer, garlic-derived S-allylmercaptocysteine, as a treatment option for hormone refractory prostate cancer.
    Howard EW; Lee DT; Chiu YT; Chua CW; Wang X; Wong YC
    Int J Cancer; 2008 May; 122(9):1941-8. PubMed ID: 18183597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic integration of c-myc and bcl-2 antisense molecules with docetaxel in a preclinical model of hormone-refractory prostate cancer.
    Leonetti C; Biroccio A; D'Angelo C; Semple SC; Scarsella M; Zupi G
    Prostate; 2007 Sep; 67(13):1475-85. PubMed ID: 17654511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sabutoclax, a Mcl-1 antagonist, inhibits tumorigenesis in transgenic mouse and human xenograft models of prostate cancer.
    Jackson RS; Placzek W; Fernandez A; Ziaee S; Chu CY; Wei J; Stebbins J; Kitada S; Fritz G; Reed JC; Chung LW; Pellecchia M; Bhowmick NA
    Neoplasia; 2012 Jul; 14(7):656-65. PubMed ID: 22904682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High expression of TROP2 characterizes different cell subpopulations in androgen-sensitive and androgen-independent prostate cancer cells.
    Xie J; Mølck C; Paquet-Fifield S; Butler L; ; Sloan E; Ventura S; Hollande F
    Oncotarget; 2016 Jul; 7(28):44492-44504. PubMed ID: 27283984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Docetaxel induces Bcl-2- and pro-apoptotic caspase-independent death of human prostate cancer DU145 cells.
    Ogura T; Tanaka Y; Tamaki H; Harada M
    Int J Oncol; 2016 Jun; 48(6):2330-8. PubMed ID: 27082738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Notch Pathway Inhibition Using PF-03084014, a γ-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer.
    Cui D; Dai J; Keller JM; Mizokami A; Xia S; Keller ET
    Clin Cancer Res; 2015 Oct; 21(20):4619-29. PubMed ID: 26202948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. siRNA-mediated silencing of Notch-1 enhances docetaxel induced mitotic arrest and apoptosis in prostate cancer cells.
    Ye QF; Zhang YC; Peng XQ; Long Z; Ming YZ; He LY
    Asian Pac J Cancer Prev; 2012; 13(6):2485-9. PubMed ID: 22938409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1.
    Wang Y; Lieberman R; Pan J; Zhang Q; Du M; Zhang P; Nevalainen M; Kohli M; Shenoy NK; Meng H; You M; Wang L
    Mol Cancer; 2016 Nov; 15(1):70. PubMed ID: 27832783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of docetaxel-induced cytotoxicity and apoptosis by all-trans retinoic acid (ATRA) through downregulation of survivin (BIRC5), MCL-1 and LTbeta-R in hormone- and drug resistant prostate cancer cell line, DU-145.
    Kucukzeybek Y; Gul MK; Cengiz E; Erten C; Karaca B; Gorumlu G; Atmaca H; Uzunoglu S; Karabulut B; Sanli UA; Uslu R
    J Exp Clin Cancer Res; 2008 Sep; 27(1):37. PubMed ID: 18789152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Darinaparsin inhibits prostate tumor-initiating cells and Du145 xenografts and is an inhibitor of hedgehog signaling.
    Bansal N; Farley NJ; Wu L; Lewis J; Youssoufian H; Bertino JR
    Mol Cancer Ther; 2015 Jan; 14(1):23-30. PubMed ID: 25381261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acquisition of tumorigenic potential and therapeutic resistance in CD133+ subpopulation of prostate cancer cells exhibiting stem-cell like characteristics.
    Kanwal R; Shukla S; Walker E; Gupta S
    Cancer Lett; 2018 Aug; 430():25-33. PubMed ID: 29775627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relaxin receptor antagonist AT-001 synergizes with docetaxel in androgen-independent prostate xenografts.
    Neschadim A; Pritzker LB; Pritzker KP; Branch DR; Summerlee AJ; Trachtenberg J; Silvertown JD
    Endocr Relat Cancer; 2014 Jun; 21(3):459-71. PubMed ID: 24812057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of prostate cancer progression by cancer cell stemness inhibitor napabucasin.
    Zhang Y; Jin Z; Zhou H; Ou X; Xu Y; Li H; Liu C; Li B
    Cancer Med; 2016 Jun; 5(6):1251-8. PubMed ID: 26899963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GLIPR1-ΔTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells.
    Karanika S; Karantanos T; Kurosaka S; Wang J; Hirayama T; Yang G; Park S; Golstov AA; Tanimoto R; Li L; Thompson TC
    Mol Cancer; 2015 Jun; 14():122. PubMed ID: 26084402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1α and sphingosine kinase 1.
    Alshaker H; Wang Q; Kawano Y; Arafat T; Böhler T; Winkler M; Cooper C; Pchejetski D
    Oncotarget; 2016 Dec; 7(49):80943-80956. PubMed ID: 27821815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.